Prime Medicine Inc. (PRME)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
Prime Medicine Beats Beam Therapeutics In Patent Dispute - But Both Are Investable
Prime Medicine, Inc. secured a favorable arbitration ruling against Beam Therapeutics, allowing continued development of its PM647 gene editing program for AATD. PRME's Prime Editing platform offers precise, versatile gene correction using LNP delivery, but remains preclinical with IND/CTA filings for PM647 expected mid-2026 and initial clinical data in 2027. PRME lags competitors like Beam, Sanofi, and Arrowhead in the AATD development race, facing significant funding needs and clinical risks.
Prime Medicine's Prime Editing Is Worth The Risk
Prime Medicine's PM359 data gives the stock some early human validation for its main value driver: Prime Editing. PM359 was essentially their most advanced application of Prime Editing, even though CGD is a relatively niche market because it's a rare disease. Management decided to deprioritize PM359, and instead, it's now focused on applying Prime Editing towards larger TAMs like Wilson Disease and AATD.
Prime Medicine, Inc. (PRME) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Prepared Remarks Transcript
Prime Medicine, Inc. (PRME) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Prepared Remarks Transcript
Prime Medicine Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| CE Curtis Ellergodt Rothschild Investment LLC | 345 | $961.75 | $1,191.97 | $230.22 | 23.94% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 74 | $257.52 | $251.6 | -$5.92 | -2.3% |
 Farallon Capital Farallon Capital Management LLC | 1.24M | $6.87M | $4.27M | -$2.6M | -37.81% |
| BG Bart Gancher Intech Investment Management LLC | 30,538 | $78,246.46 | $103,926.92 | $25,680.46 | 32.82% |
 Joseph Castro Nuveen LLC | 275,931 | $758,470.86 | $939,545.05 | $181,074.19 | 23.87% |
Prime Medicine Inc. (PRME) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Prime Medicine Inc. ever had a stock split?
Prime Medicine Inc. Profile
| Biotechnology Industry | Healthcare Sector | Allan Reine CEO | NASDAQ (NMS) Exchange | 74168J101 CUSIP |
| US Country | 146 Employees | - Last Dividend | - Last Split | 20 Oct 2022 IPO Date |
Overview
Prime Medicine, Inc. is a biotechnology enterprise specialized in pioneering genetic therapies to combat a broad spectrum of diseases by harnessing the power of gene editing technology. Established in 2019, the company positions itself at the forefront of genetic medicine with its innovative approach to editing DNA sequences. Operating from its headquarters in Cambridge, Massachusetts, Prime Medicine is dedicated to realizing the potential of genetic correction and modification to treat conditions that have long been considered untreatable. The company has embarked on a significant collaboration with Cimeio Therapeutics, focusing on the development of Prime Edited Shielded-Cell & Immunotherapy Pairs, targeting genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome.
Products and Services
- Prime Editors
- Collaborative Research Projects
At the core of Prime Medicine's offerings are the Prime Editors, a revolutionary gene editing tool. This technology combines a Prime Editor protein, which is a fusion of a Cas protein and a reverse transcriptase enzyme, with a pegRNA (prime editing guide RNA). The pegRNA is crucial as it not only directs the Prime Editor to a specific location within the genome but also supplies the template needed for executing the desired edit on the target DNA sequence. This sophisticated mechanism allows for precision in gene editing, paving the way for treatment strategies that could correct genetic mutations at their source.
Underpinning Prime Medicine's innovative technology is its strategic research collaboration with Cimeio Therapeutics. This partnership is primarily focused on the development of Prime Edited Shielded-Cell & Immunotherapy Pairs. These novel therapeutic strategies are designed to treat a range of conditions, from genetic diseases to cancers like acute myeloid leukemia and myelodysplastic syndrome. This collaboration highlights Prime Medicine's commitment to leveraging its technology in concert with other biotech entities to address complex medical challenges.
